RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport
Identifieur interne : 002C81 ( Main/Corpus ); précédent : 002C80; suivant : 002C82RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport
Auteurs : Timothy M. Fountaine ; Richard Wade-MartinsSource :
- Journal of Neuroscience Research [ 0360-4012 ] ; 2007-02-01.
English descriptors
- KwdEn :
Abstract
The critical observation in the pathology of Parkinson's disease (PD) is that neurodegeneration is largely restricted to dopaminergic neurons that develop cytoplasmic inclusions called Lewy bodies. These aggregations contain the protein α‐synuclein. Furthermore, it is becoming apparent that α‐synuclein expression levels are a major factor in PD pathogenesis. Patients with additional copies of the α‐synuclein gene develop PD with a severity proportional to levels of α‐synuclein overexpression. Similarly, overexpression of α‐synuclein in in vitro and in vivo models has been shown to be toxic. However, little is known about the effects of reducing α‐synuclein expression in human neurons. To investigate this, we have developed a system in which levels of α‐synuclein can be acutely suppressed by using RNA interference (RNAi) in a physiologically relevant human dopaminergic cellular model. By using small interfering RNA (siRNA) molecules targeted to endogenous α‐synuclein, we achieved 80% protein knockdown. We show that α‐synuclein knockdown has no effect on cellular survival either under normal growth conditions over 5 days or in the presence of the mitochondrial inhibitor rotenone. Knockdown does, however, confer resistance to the dopamine transporter (DAT)‐dependent neurotoxin N‐methyl‐4‐phenylpyridinium (MPP+). We then demonstrate for the first time that α‐synuclein suppression decreases dopamine transport in human cells, reducing the maximal uptake velocity (Vmax) of dopamine and the surface density of its transporter by up to 50%. These results show that RNAi‐mediated α‐synuclein knockdown alters cellular dopamine homeostasis in human cells and may suggest a mechanism for the increased survival in the presence of MPP+, a toxin used extensively to model Parkinson's disease. © 2006 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jnr.21125
Links to Exploration step
ISTEX:23B43DAE5A3BCDC8F3AD735046C24E491BFA5507Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport</title><author><name sortKey="Fountaine, Timothy M" sort="Fountaine, Timothy M" uniqKey="Fountaine T" first="Timothy M." last="Fountaine">Timothy M. Fountaine</name><affiliation><mods:affiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Wade Artins, Richard" sort="Wade Artins, Richard" uniqKey="Wade Artins R" first="Richard" last="Wade-Martins">Richard Wade-Martins</name><affiliation><mods:affiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:23B43DAE5A3BCDC8F3AD735046C24E491BFA5507</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/jnr.21125</idno><idno type="url">https://api.istex.fr/document/23B43DAE5A3BCDC8F3AD735046C24E491BFA5507/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002C81</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport</title><author><name sortKey="Fountaine, Timothy M" sort="Fountaine, Timothy M" uniqKey="Fountaine T" first="Timothy M." last="Fountaine">Timothy M. Fountaine</name><affiliation><mods:affiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Wade Artins, Richard" sort="Wade Artins, Richard" uniqKey="Wade Artins R" first="Richard" last="Wade-Martins">Richard Wade-Martins</name><affiliation><mods:affiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="ISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-02-01">2007-02-01</date><biblScope unit="volume">85</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="351">351</biblScope><biblScope unit="page" to="363">363</biblScope></imprint><idno type="ISSN">0360-4012</idno></series><idno type="istex">23B43DAE5A3BCDC8F3AD735046C24E491BFA5507</idno><idno type="DOI">10.1002/jnr.21125</idno><idno type="ArticleID">JNR21125</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-4012</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DAT</term><term>MPTP</term><term>Parkinson's disease</term><term>neurodegeneration</term><term>rotenone</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The critical observation in the pathology of Parkinson's disease (PD) is that neurodegeneration is largely restricted to dopaminergic neurons that develop cytoplasmic inclusions called Lewy bodies. These aggregations contain the protein α‐synuclein. Furthermore, it is becoming apparent that α‐synuclein expression levels are a major factor in PD pathogenesis. Patients with additional copies of the α‐synuclein gene develop PD with a severity proportional to levels of α‐synuclein overexpression. Similarly, overexpression of α‐synuclein in in vitro and in vivo models has been shown to be toxic. However, little is known about the effects of reducing α‐synuclein expression in human neurons. To investigate this, we have developed a system in which levels of α‐synuclein can be acutely suppressed by using RNA interference (RNAi) in a physiologically relevant human dopaminergic cellular model. By using small interfering RNA (siRNA) molecules targeted to endogenous α‐synuclein, we achieved 80% protein knockdown. We show that α‐synuclein knockdown has no effect on cellular survival either under normal growth conditions over 5 days or in the presence of the mitochondrial inhibitor rotenone. Knockdown does, however, confer resistance to the dopamine transporter (DAT)‐dependent neurotoxin N‐methyl‐4‐phenylpyridinium (MPP+). We then demonstrate for the first time that α‐synuclein suppression decreases dopamine transport in human cells, reducing the maximal uptake velocity (Vmax) of dopamine and the surface density of its transporter by up to 50%. These results show that RNAi‐mediated α‐synuclein knockdown alters cellular dopamine homeostasis in human cells and may suggest a mechanism for the increased survival in the presence of MPP+, a toxin used extensively to model Parkinson's disease. © 2006 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Timothy M. Fountaine</name><affiliations><json:string>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</json:string></affiliations></json:item><json:item><name>Richard Wade‐Martins</name><affiliations><json:string>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>DAT</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rotenone</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MPTP</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurodegeneration</value></json:item></subject><articleId><json:string>JNR21125</json:string></articleId><language><json:string>eng</json:string></language><abstract>The critical observation in the pathology of Parkinson's disease (PD) is that neurodegeneration is largely restricted to dopaminergic neurons that develop cytoplasmic inclusions called Lewy bodies. These aggregations contain the protein α‐synuclein. Furthermore, it is becoming apparent that α‐synuclein expression levels are a major factor in PD pathogenesis. Patients with additional copies of the α‐synuclein gene develop PD with a severity proportional to levels of α‐synuclein overexpression. Similarly, overexpression of α‐synuclein in in vitro and in vivo models has been shown to be toxic. However, little is known about the effects of reducing α‐synuclein expression in human neurons. To investigate this, we have developed a system in which levels of α‐synuclein can be acutely suppressed by using RNA interference (RNAi) in a physiologically relevant human dopaminergic cellular model. By using small interfering RNA (siRNA) molecules targeted to endogenous α‐synuclein, we achieved 80% protein knockdown. We show that α‐synuclein knockdown has no effect on cellular survival either under normal growth conditions over 5 days or in the presence of the mitochondrial inhibitor rotenone. Knockdown does, however, confer resistance to the dopamine transporter (DAT)‐dependent neurotoxin N‐methyl‐4‐phenylpyridinium (MPP+). We then demonstrate for the first time that α‐synuclein suppression decreases dopamine transport in human cells, reducing the maximal uptake velocity (Vmax) of dopamine and the surface density of its transporter by up to 50%. These results show that RNAi‐mediated α‐synuclein knockdown alters cellular dopamine homeostasis in human cells and may suggest a mechanism for the increased survival in the presence of MPP+, a toxin used extensively to model Parkinson's disease. © 2006 Wiley‐Liss, Inc.</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1827</abstractCharCount><pdfWordCount>7677</pdfWordCount><pdfCharCount>47809</pdfCharCount><pdfPageCount>13</pdfPageCount><abstractWordCount>260</abstractWordCount></qualityIndicators><title>RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport</title><genre><json:string>article</json:string></genre><host><volume>85</volume><publisherId><json:string>JNR</json:string></publisherId><pages><total>13</total><last>363</last><first>351</first></pages><issn><json:string>0360-4012</json:string></issn><issue>2</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1097-4547</json:string></eissn><title>Journal of Neuroscience Research</title><doi><json:string>10.1002/(ISSN)1097-4547</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/jnr.21125</json:string></doi><id>23B43DAE5A3BCDC8F3AD735046C24E491BFA5507</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/23B43DAE5A3BCDC8F3AD735046C24E491BFA5507/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/23B43DAE5A3BCDC8F3AD735046C24E491BFA5507/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/23B43DAE5A3BCDC8F3AD735046C24E491BFA5507/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><notesStmt><note>The Wellcome Trust</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport</title><author><persName><forename type="first">Timothy M.</forename><surname>Fountaine</surname></persName><affiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</affiliation></author><author><persName><forename type="first">Richard</forename><surname>Wade‐Martins</surname></persName><note type="correspondence"><p>Correspondence: The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom</p></note><affiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</affiliation></author></analytic><monogr><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="pISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><idno type="DOI">10.1002/(ISSN)1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-02-01"></date><biblScope unit="volume">85</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="351">351</biblScope><biblScope unit="page" to="363">363</biblScope></imprint></monogr><idno type="istex">23B43DAE5A3BCDC8F3AD735046C24E491BFA5507</idno><idno type="DOI">10.1002/jnr.21125</idno><idno type="ArticleID">JNR21125</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The critical observation in the pathology of Parkinson's disease (PD) is that neurodegeneration is largely restricted to dopaminergic neurons that develop cytoplasmic inclusions called Lewy bodies. These aggregations contain the protein α‐synuclein. Furthermore, it is becoming apparent that α‐synuclein expression levels are a major factor in PD pathogenesis. Patients with additional copies of the α‐synuclein gene develop PD with a severity proportional to levels of α‐synuclein overexpression. Similarly, overexpression of α‐synuclein in in vitro and in vivo models has been shown to be toxic. However, little is known about the effects of reducing α‐synuclein expression in human neurons. To investigate this, we have developed a system in which levels of α‐synuclein can be acutely suppressed by using RNA interference (RNAi) in a physiologically relevant human dopaminergic cellular model. By using small interfering RNA (siRNA) molecules targeted to endogenous α‐synuclein, we achieved 80% protein knockdown. We show that α‐synuclein knockdown has no effect on cellular survival either under normal growth conditions over 5 days or in the presence of the mitochondrial inhibitor rotenone. Knockdown does, however, confer resistance to the dopamine transporter (DAT)‐dependent neurotoxin N‐methyl‐4‐phenylpyridinium (MPP+). We then demonstrate for the first time that α‐synuclein suppression decreases dopamine transport in human cells, reducing the maximal uptake velocity (Vmax) of dopamine and the surface density of its transporter by up to 50%. These results show that RNAi‐mediated α‐synuclein knockdown alters cellular dopamine homeostasis in human cells and may suggest a mechanism for the increased survival in the presence of MPP+, a toxin used extensively to model Parkinson's disease. © 2006 Wiley‐Liss, Inc.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>DAT</term></item><item><term>rotenone</term></item><item><term>MPTP</term></item><item><term>neurodegeneration</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-07-05">Received</change><change when="2006-09-26">Registration</change><change when="2007-02-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/23B43DAE5A3BCDC8F3AD735046C24E491BFA5507/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1097-4547</doi><issn type="print">0360-4012</issn><issn type="electronic">1097-4547</issn><idGroup><id type="product" value="JNR"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="JOURNAL OF NEUROSCIENCE RESEARCH">Journal of Neuroscience Research</title><title type="short">J. Neurosci. Res.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/jnr.v85:2</doi><numberingGroup><numbering type="journalVolume" number="85">85</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2007-02-01">1 February 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/jnr.21125</doi><idGroup><id type="unit" value="JNR21125"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2006 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptReceived" date="2006-07-05"></event><event type="manuscriptRevised" date="2006-09-05"></event><event type="manuscriptAccepted" date="2006-09-26"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-11-27"></event><event type="firstOnline" date="2006-11-27"></event><event type="publishedOnlineFinalForm" date="2007-01-16"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-15"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-31"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event></eventGroup><numberingGroup><numbering type="pageFirst">351</numbering><numbering type="pageLast">363</numbering></numberingGroup><correspondenceTo>The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JNR.JNR21125.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="7"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="52"></count><count type="wordTotal" number="8889"></count></countGroup><titleGroup><title type="main" xml:lang="en">RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP<sup>+</sup> toxicity and reduces dopamine transport</title><title type="short" xml:lang="en">RNAi Knockdown of α‐Synuclein</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Timothy M.</givenNames><familyName>Fountaine</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Richard</givenNames><familyName>Wade‐Martins</familyName></personName><contactDetails><email normalForm="richard.wade-martins@well.ox.ac.uk">richard.wade‐martins@well.ox.ac.uk</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">DAT</keyword><keyword xml:id="kwd3">rotenone</keyword><keyword xml:id="kwd4">MPTP</keyword><keyword xml:id="kwd5">neurodegeneration</keyword></keywordGroup><fundingInfo><fundingAgency>The Wellcome Trust</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The critical observation in the pathology of Parkinson's disease (PD) is that neurodegeneration is largely restricted to dopaminergic neurons that develop cytoplasmic inclusions called Lewy bodies. These aggregations contain the protein α‐synuclein. Furthermore, it is becoming apparent that α‐synuclein expression levels are a major factor in PD pathogenesis. Patients with additional copies of the α‐synuclein gene develop PD with a severity proportional to levels of α‐synuclein overexpression. Similarly, overexpression of α‐synuclein in in vitro and in vivo models has been shown to be toxic. However, little is known about the effects of reducing α‐synuclein expression in human neurons. To investigate this, we have developed a system in which levels of α‐synuclein can be acutely suppressed by using RNA interference (RNAi) in a physiologically relevant human dopaminergic cellular model. By using small interfering RNA (siRNA) molecules targeted to endogenous α‐synuclein, we achieved 80% protein knockdown. We show that α‐synuclein knockdown has no effect on cellular survival either under normal growth conditions over 5 days or in the presence of the mitochondrial inhibitor rotenone. Knockdown does, however, confer resistance to the dopamine transporter (DAT)‐dependent neurotoxin N‐methyl‐4‐phenylpyridinium (MPP<sup>+</sup>). We then demonstrate for the first time that α‐synuclein suppression decreases dopamine transport in human cells, reducing the maximal uptake velocity (V<sub>max</sub>) of dopamine and the surface density of its transporter by up to 50%. These results show that RNAi‐mediated α‐synuclein knockdown alters cellular dopamine homeostasis in human cells and may suggest a mechanism for the increased survival in the presence of MPP<sup>+</sup>, a toxin used extensively to model Parkinson's disease. © 2006 Wiley‐Liss, Inc.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>RNAi Knockdown of α‐Synuclein</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP</title></titleInfo><name type="personal"><namePart type="given">Timothy M.</namePart><namePart type="family">Fountaine</namePart><affiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Wade‐Martins</namePart><affiliation>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom</affiliation><description>Correspondence: The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-02-01</dateIssued><dateCaptured encoding="w3cdtf">2006-07-05</dateCaptured><dateValid encoding="w3cdtf">2006-09-26</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">7</extent><extent unit="tables">1</extent><extent unit="references">52</extent><extent unit="words">8889</extent></physicalDescription><abstract lang="en">The critical observation in the pathology of Parkinson's disease (PD) is that neurodegeneration is largely restricted to dopaminergic neurons that develop cytoplasmic inclusions called Lewy bodies. These aggregations contain the protein α‐synuclein. Furthermore, it is becoming apparent that α‐synuclein expression levels are a major factor in PD pathogenesis. Patients with additional copies of the α‐synuclein gene develop PD with a severity proportional to levels of α‐synuclein overexpression. Similarly, overexpression of α‐synuclein in in vitro and in vivo models has been shown to be toxic. However, little is known about the effects of reducing α‐synuclein expression in human neurons. To investigate this, we have developed a system in which levels of α‐synuclein can be acutely suppressed by using RNA interference (RNAi) in a physiologically relevant human dopaminergic cellular model. By using small interfering RNA (siRNA) molecules targeted to endogenous α‐synuclein, we achieved 80% protein knockdown. We show that α‐synuclein knockdown has no effect on cellular survival either under normal growth conditions over 5 days or in the presence of the mitochondrial inhibitor rotenone. Knockdown does, however, confer resistance to the dopamine transporter (DAT)‐dependent neurotoxin N‐methyl‐4‐phenylpyridinium (MPP+). We then demonstrate for the first time that α‐synuclein suppression decreases dopamine transport in human cells, reducing the maximal uptake velocity (Vmax) of dopamine and the surface density of its transporter by up to 50%. These results show that RNAi‐mediated α‐synuclein knockdown alters cellular dopamine homeostasis in human cells and may suggest a mechanism for the increased survival in the presence of MPP+, a toxin used extensively to model Parkinson's disease. © 2006 Wiley‐Liss, Inc.</abstract><note type="funding">The Wellcome Trust</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>DAT</topic><topic>rotenone</topic><topic>MPTP</topic><topic>neurodegeneration</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Neuroscience Research</title></titleInfo><titleInfo type="abbreviated"><title>J. Neurosci. Res.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0360-4012</identifier><identifier type="eISSN">1097-4547</identifier><identifier type="DOI">10.1002/(ISSN)1097-4547</identifier><identifier type="PublisherID">JNR</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>351</start><end>363</end><total>13</total></extent></part></relatedItem><identifier type="istex">23B43DAE5A3BCDC8F3AD735046C24E491BFA5507</identifier><identifier type="DOI">10.1002/jnr.21125</identifier><identifier type="ArticleID">JNR21125</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002C81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:23B43DAE5A3BCDC8F3AD735046C24E491BFA5507
|texte= RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport
}}
| This area was generated with Dilib version V0.6.23. |  |